Rodman & Renshaw's Raghuram Selvaraju reiterated his Buy position on Synergy Pharmaceuticals Inc SGYP with a price target of $15.00. The rating reiteration comes after further Plecanatide Phase 3 data was reported, showing positive results.
The new data "emphasizes what we view as the drug's strong likelihood of approval early next year," said Selvaraju. Due to further "top-line data release from two ongoing Phase 3 trials of plecanatide" later this year, the analyst believed the price is likely to rise from $3.26 to $15.00 over the next twelve months.
Selvaraju did acknowledge three significant risks to the company, which include:
- Plecanatide failure in clinical trials
- Failure of plecanatide to secure approval
- "Variations in market size, penetration and pricing vs. our model estimates"
Despite Selvaraju's positive outlook for the company, the analyst estimates 2017 EPS to be $(0.29).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.